NCT05975840 - Safety and Immunogenicity of Different Formulations of Monovalent Influenza A/Astrakhan/3212/2020 Like (H5N8) Virus Vaccine With AS03 Adjuvant System in Medically Stable Adults | Biotech Hunter

Enrollment

518

Participants

Timeline

Start Date

August 3, 2023

Primary Completion Date

May 21, 2024

Study Completion Date

September 19, 2024

Conditions

Influenza, Human

Interventions

BIOLOGICAL

FLU Q-PAN H5N8 375_B

Participants received 2 doses of 375\_B vaccine formulation by intramuscular injection in the non-dominant arm.

BIOLOGICAL

FLU Q-PAN H5N8 375_A

Participants received 2 doses of 375\_A vaccine formulation by intramuscular injection in the non-dominant arm.

BIOLOGICAL

FLU Q-PAN H5N8 750_B

Participants received 2 doses of 750\_B vaccine formulation by intramuscular injection in the non-dominant arm.

BIOLOGICAL

FLU Q-PAN H5N8 750_A

Participants received 2 doses of 750\_A vaccine formulation by intramuscular injection in the non-dominant arm.

Trial Locations (20)

23507

GSK Investigational Site, Norfolk

29621

GSK Investigational Site, Anderson

30341

GSK Investigational Site, Chamblee

33025

GSK Investigational Site, Pembroke Pines

36207

GSK Investigational Site, Anniston

36608

GSK Investigational Site, Mobile

37920

GSK Investigational Site, Knoxville

40509

GSK Investigational Site, Lexington

66219

GSK Investigational Site, Lenexa

67042

GSK Investigational Site, El Dorado

70006

GSK Investigational Site, Metairie

77375

GSK Investigational Site, Tomball

78006

GSK Investigational Site, Boerne

78244

GSK Investigational Site, San Antonio

78745

GSK Investigational Site, Austin

83642

GSK Investigational Site, Meridian

85281

GSK Investigational Site, Tempe

90806

GSK Investigational Site, Long Beach

91911

GSK Investigational Site, Chula Vista

92705

GSK Investigational Site, Santa Ana